FDA sets December approval decision for first CRISPR therapy, with 94% of patients free of sickle cell crises

Near­ly 11 years ago, sci­en­tists pro­grammed a pair of mol­e­c­u­lar scis­sors to make pre­cise cuts in DNA. That first test tube ex­per­i­ment of CRISPR gene edit­ing tech­nol­o­gy won its cre­ators a No­bel Prize, ig­nit­ed a gene edit­ing rev­o­lu­tion in life sci­ence labs, and kick-start­ed a race to de­vel­op gene-al­ter­ing med­i­cines.

Now, the fin­ish line is in sight. For the first time, a CRISPR ther­a­py is up for FDA ap­proval, Ver­tex and CRISPR Ther­a­peu­tics an­nounced Thurs­day evening.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN